DOP2010000164A - VACCINE - Google Patents

VACCINE

Info

Publication number
DOP2010000164A
DOP2010000164A DO2010000164A DO2010000164A DOP2010000164A DO P2010000164 A DOP2010000164 A DO P2010000164A DO 2010000164 A DO2010000164 A DO 2010000164A DO 2010000164 A DO2010000164 A DO 2010000164A DO P2010000164 A DOP2010000164 A DO P2010000164A
Authority
DO
Dominican Republic
Prior art keywords
viral vector
vector
seq
protein
relates
Prior art date
Application number
DO2010000164A
Other languages
Spanish (es)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000164(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of DOP2010000164A publication Critical patent/DOP2010000164A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se refiere a un vector adenovirico de simio deficiente de replicación C7 que codifica una proteina que comprende la proteina CS de P. falciparum o un fragmento de la misma, por ejemplo como se muestra en la SEC ID N° 1 o la SEC ID N° 3. La invención se refiere tambien a procedimientos de preparación de dicho vector virico y al use del vector virico en el tratamiento/prevención de infección por malaria. Se describen tambien composiciones, vacunas y kits que comprenden dicho vector virico. En un aspecto, la invención emplea un vector virico C7 sintetico. El vector virico C7 segun la invención puede coadministrarse o coformularse con un antigeno de la malaria tal como RTS,S, opcionalmente en presencia de un coadyuvante, por ejemplo, que comprende 3D-MPL y/o una saponina tal como QS21.The invention relates to a C7 replication deficient ape adenoviric vector encoding a protein comprising the P. falciparum CS protein or a fragment thereof, for example as shown in SEQ ID No. 1 or SEQ ID. No. 3. The invention also relates to methods of preparing said viral vector and the use of the viral vector in the treatment / prevention of malaria infection. Compositions, vaccines and kits comprising said viral vector are also described. In one aspect, the invention employs a C7 synthetic vector. The C7 viral vector according to the invention can be co-administered or co-formulated with a malaria antigen such as RTS, S, optionally in the presence of an adjuvant, for example, comprising 3D-MPL and / or a saponin such as QS21.

DO2010000164A 2007-12-06 2010-06-02 VACCINE DOP2010000164A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06

Publications (1)

Publication Number Publication Date
DOP2010000164A true DOP2010000164A (en) 2010-07-31

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000164A DOP2010000164A (en) 2007-12-06 2010-06-02 VACCINE

Country Status (20)

Country Link
EP (1) EP2227550A2 (en)
JP (1) JP2011505796A (en)
KR (1) KR20100108544A (en)
CN (1) CN101939438A (en)
AR (1) AR069568A1 (en)
AU (1) AU2008333208A1 (en)
BR (1) BRPI0819889A2 (en)
CA (1) CA2707245A1 (en)
CL (1) CL2008003614A1 (en)
CO (1) CO6300795A2 (en)
CR (1) CR11537A (en)
DO (1) DOP2010000164A (en)
IL (1) IL205953A0 (en)
MA (1) MA32003B1 (en)
MX (1) MX2010006207A (en)
PE (1) PE20091106A1 (en)
TW (1) TW200938633A (en)
UY (1) UY31510A1 (en)
WO (1) WO2009071613A2 (en)
ZA (1) ZA201003851B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
CN103596586A (en) * 2011-04-08 2014-02-19 免疫设计公司 Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110687289B (en) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Application of FGL2 protein as malaria infection marker

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
PL376792A1 (en) * 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
NZ539813A (en) * 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
WO2005063805A1 (en) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
CA2880061C (en) * 2004-01-23 2018-03-13 Agostino Cirillo Chimpanzee adenovirus vaccine carriers
PT1802336E (en) * 2004-10-14 2011-11-15 Glaxosmithkline Biolog Sa Malaria prime/boost vaccines
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2007110409A1 (en) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
AU2007276217B2 (en) * 2006-07-18 2013-08-29 Glaxosmithkline Biologicals S.A. Vaccines for malaria
MX2009009342A (en) * 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Novel method and compositions.
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors

Also Published As

Publication number Publication date
WO2009071613A2 (en) 2009-06-11
EP2227550A2 (en) 2010-09-15
MA32003B1 (en) 2011-01-03
WO2009071613A3 (en) 2009-08-13
ZA201003851B (en) 2012-11-28
JP2011505796A (en) 2011-03-03
CL2008003614A1 (en) 2010-01-15
CR11537A (en) 2010-08-18
AU2008333208A1 (en) 2009-06-11
CN101939438A (en) 2011-01-05
BRPI0819889A2 (en) 2015-06-16
KR20100108544A (en) 2010-10-07
UY31510A1 (en) 2009-08-03
PE20091106A1 (en) 2009-08-24
CO6300795A2 (en) 2011-07-21
CA2707245A1 (en) 2009-06-11
MX2010006207A (en) 2010-10-04
TW200938633A (en) 2009-09-16
IL205953A0 (en) 2010-11-30
AR069568A1 (en) 2010-02-03

Similar Documents

Publication Publication Date Title
MX2022005291A (en) Vaccines for treatment and prevention of cancer.
CY1117673T1 (en) Recombinant RSV antigens
CY1119284T1 (en) PARTICULAR SUBJECTS WITH VIRUS-PROTEIN SOLUTIONS (VLPs)
EA201070794A1 (en) Recombinant antigens RSV
MX347997B (en) Newcastle disease virus vectored avian vaccines.
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
ES2585328T3 (en) Non-lipidated variants of ORF2086 antigens from Neisseria meningitidis
PE20190420A1 (en) SOLUBLE AND STABILIZED RESPIRATORY SYNCITIAL VIRUS (RSV) PREFUSION PROTEINS F
MX2011011505A (en) Pneumococcal vaccine and uses thereof.
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
PE20130324A1 (en) FUSION PROTEINS INCLUDING AN ANTIGEN PRAME (DAGE)
AR093712A1 (en) IMMUNOGEN COMPOSITION, VACCINE, USE AND PROCEDURE FOR PREVENTION OR TREATMENT
WO2018193063A3 (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
EA201290956A1 (en) VACCINE AGAINST HIV
WO2008054535A3 (en) Novel influenza m2 vaccines
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
DOP2010000164A (en) VACCINE
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
MX2016001695A (en) Combination immunogenic compositions.
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
UA102274C2 (en) Epitope peptid rab6kifl/kif20a and vaccines containing it
WO2013171661A3 (en) Adjuvant formulations and methods
EA201200538A1 (en) ARABINOGALAKTAN TO IMPROVE ACQUIRED IMMUNE RESPONSE